0000899243-20-032050.txt : 20201124 0000899243-20-032050.hdr.sgml : 20201124 20201124173639 ACCESSION NUMBER: 0000899243-20-032050 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201123 FILED AS OF DATE: 20201124 DATE AS OF CHANGE: 20201124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P. CENTRAL INDEX KEY: 0001787092 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39712 FILM NUMBER: 201345577 BUSINESS ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (617) 951-5372 MAIL ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (415) 651-3316 MAIL ADDRESS: STREET 1: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-23 1 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001787092 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 0 0 1 0 Common Stock 2020-11-23 4 C 0 1273420 A 1273420 D Common Stock 2020-11-23 4 C 0 451986 A 1725406 D Series B Preferred Stock 2020-11-23 4 C 0 1273420 0.00 D Common Stock 1273420 0 D Series C Preferred Stock 2020-11-23 4 C 0 451986 0.00 D Common Stock 451986 0 D Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date. Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Advisor, /s/ Peter McIsaac, Title: Authorized Person 2020-11-23